Initial results of the first two-phase trials of the vaccine conducted in five trial sites in the U.K. showed it has an acceptable safety profile and homologous boosting increased antibody responses, the source said
Initial results of the first two-phase trials of the vaccine conducted in five trial sites in the U.K. showed it has an acceptable safety profile and homologous boosting increased antibody responses, the source said